Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096674 · ClinicalTrials.gov registry record · Phase 2
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
A Phase 2 study of Idiopathic Hypersomnia and Narcolepsy Type 1, sponsored by Centessa Pharmaceuticals (UK) Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 14
- Study locations
NCT07096674: Recruiting Phase 2 study of Idiopathic Hypersomnia and Narcolepsy Type 1, sponsored by Centessa Pharmaceuticals (UK) Limited.
NCT07096674 is a Phase 2 study of Idiopathic Hypersomnia and Narcolepsy Type 1 that is actively recruiting participants, run by Centessa Pharmaceuticals (UK) Limited. The registered enrollment target is 90 participants, below the 108-participant average among 7 other Idiopathic Hypersomnia trials with a reported enrollment target (17% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07096674, a Phase 2 study of Idiopathic Hypersomnia and Narcolepsy Type 1, is actively recruiting participants, sponsored by Centessa Pharmaceuticals (UK) Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Primary Outcome
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Conditions Studied
Interventions
- DRUG ORX750
Study Locations (14)
Georgia
- Atlanta, Georgia - Atlanta
- Atlanta, Georgia - Atlanta
North Carolina
- Denver, North Carolina - Denver
- Huntersville, North Carolina - Huntersville
Texas
- Austin, Texas - Austin
- El Paso, Texas - El Paso
Alabama
- Auburn, alabama - Auburn
California
- Santa Ana, California - Santa Ana
Florida
- Miami, Florida - Miami
Michigan
- Sterling Heights, Michigan - Sterling Heights
Nevada
- Hendersen, Navada - Henderson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What NCT07096674 shows while recruiting
NCT07096674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 108-participant average among 7 other Idiopathic Hypersomnia trials with a reported enrollment target (17% lower).
The record links to 3 conditions, with Idiopathic Hypersomnia appearing as the primary indexed condition, and to 1 intervention - of which ORX750 is the first listed.
NCT07096674 lists 14 locations in 11 states (Georgia, North Carolina, Texas).
Frequently Asked Questions
What is clinical trial NCT07096674 about?
NCT07096674 is a clinical study titled "A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia". This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
What is the current status of trial NCT07096674?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-08-12. Estimated completion is 2026-04-30.
What conditions does trial NCT07096674 study?
This clinical trial studies the following conditions: Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2.
What interventions are being tested in trial NCT07096674?
The interventions under investigation include: ORX750 (DRUG).
Who is sponsoring clinical trial NCT07096674?
This trial is sponsored by Centessa Pharmaceuticals (UK) Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096674 being conducted?
This trial has 14 study locations across Alabama, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Hypersomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
RECRUITING · Phase 2
-
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
RECRUITING · Phase 2
-
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
RECRUITING · Phase 2
-
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
RECRUITING · Phase 4
-
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI